A study that looks at how well FDG-PET/CT diagnostics work in evaluating the response of bone-dominant metastatic breast cancer
N/A
Trial Summary
This study compares the effects of hypo-fractionated radiation therapy (RT) alone and RT with immunotherapy combinations. Hypo-fractionated RT differs from traditional radiotherapy in that it delivers higher doses of radiation per treatment session, resulting in fewer sessions overall. The study involves participants who are post-menopausal with early-stage of breast cancer. This study divides patients who have received 4 months of standard hormonal therapy into 4 groups, where they then receive hypo-fractionated RT alone or with different immunotherapy combinations.
Trial Design
134 patients with bone-dominant metastatic breast cancer will be recruited. They will all be assigned to the experimental group, where they would receive FDG-PET/CT procedures over 15-30 minutes and be followed up periodically for up to 3 years.
Inclusion Criteria
1. Have bone-dominant metastatic breast cancer
2. Above 18 years old
3. Life expectancy >= 24 weeks
Exclusion Criteria
1. Currently pregnant
Exclusion criteria are conditions or characteristics if they apply to you, may likely make you ineligible to participate in the study.
Inclusion criteria is a checklist of items, if they apply to you, may make you eligible to be included for the study.